Our daily analysis of a stock with a major event/upside: Geron’s potential with Imetelstat and its agonizingly slow progress towards the market
Geron (GERN) imetelstat can potentially bring about a paradigm shift in non-solid cancer therapeutics. Imet inhibits telomerase, an enzyme that enables malignant cells to replicate with its DNA intact by protecting the ends of chromosomes. Most types of tumors use the telomerase pathway to replicate, and therefore, this approach has the potential to bring about great therapeutic benefit.
Read the full analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.